Previous studies undertaken in order to investigate the role of MSCs in tumor progression have primarily focused on the effect of MSCs on tumor growth. Most of these studies showed that MSCs stimulate cancer cell growth in vitro and in vivo [17, 18, 19, 20] . Of note, in immunocompetent mice, this growth-stimulatory effect of MSCs on cancer may also be indirect, as MSCs are able to down-modulate the activities of various immune cells, including anticancer effector cells [2, 20, 21] . In addition to their growth-stimulatory activity, MSCs have also been shown to cause breast cancer cells to become more metastatic [19] . This effect seems to be mediated by the chemokine CCL5 (Rantes) [19] , one of the many proteins secreted by MSCs [22] . CCL5 is recognized by the CCR5 receptor expressed on breast cancer cells. Even so, some studies suggest that MSCs may have antitumor activities as well [23, 24, 25, 26] .
There is also evidence that MSCs may alter cell-cell adhesion [27, 28] . We addressed this occurrence by using 3-dimensional (3D) cultures of breast cancer cells. In 3D cultures, breast cancer cells form either spheroids or aggregates of irregular shape [29] . Spheroids are generated by less aggressive breast cancer cells, which still retain characteristics of normal breast epithelial cells. Also, spheroids are thought to recapitulate to some degree the glandular structure in vivo [30] and hence provide an in vitro experimental model more closely mimicking in vivo conditions. When we added GFP (green fluorescent protein)-labeled hMSCs to breast cancer spheroids, we found that the MSCs enter the spheroids and alter spheroid morphology. Immunohistochemical analysis revealed that cell-cell adhesion was disturbed in hMSCtreated spheroids. With the cell-cell adhesion weakened, breast cancer cells also showed higher motility. The main reason for these changes seemed to be the shedding of E-cadherin, the major glue between epithelial cells. In search for the mechanism, we observed that E-cadherin shedding and hMSC-induced migration could be blocked by both the ADAM10 inhibitor GI254023X and by an ADAM10-specific small-interference RNA. This outcome indicated that hMSC targeted ADAM10 to induce E-cadherin fragmentation, which then triggered the loss of cell-cell contact and cell migration (Fig. 1) . Given these data, we wondered whether E-cadherin-deficient breast cancer cells would also benefit from hMSCs. Loss of E-cadherin is often observed in the course of cancer progression, resulting in cells with a mesenchymal phenotype characterized, among others, by fibroblast-like morphology, higher motility, and by a failure to form spheroids in 3D cultures [29, 31] . When such E-cadherin-deficient breast cancer cells were incubated with hMSCs, migration was only marginally up-regulated, suggesting that Ecadherin/ADAM10 is indeed a major route through which hMSCs manipulate breast cancer cells. To stimulate ADAM10, either hMSCs could interact with breast cancer cells directly or they could secrete a soluble factor to which the cancer cells respond. To test this premise, we examined the effect of hMSCconditioned medium, a cell-free medium that contains factors secreted by MSCs, on breast cancer migration. We learned that the conditioned medium was almost as effective as hMSCs in promoting breast cancer motility.
The acquisition of the migratory potential is an important step in cancer progression, allowing cancer cells to migrate into adjacent tissue [32] . Our data suggest that hMSCs enhance this potential by activating a protease that down-regulates cell-cell adhesion and, thereby, most likely promoting cancer progression. Interestingly, we found that hMSCs have little effect on the motility of more aggressive mesenchymal breast cancer cells that already had lost E-cadherin [10] . Instead, these per se highly motile cells "benefit" from the interaction with hMSCs in a different way in that they acquire an increased potential to metastasize [19] . It almost seems as though hMSCs modulate the behavior of breast cancer cells in the way the cancer benefits most. This result is consistent with the idea that the hMSC is a "repair cell", one that serves injured tissue by meeting their specific need for efficient healing. Cancer is regarded as "a wound that never heals". Hence it may be that by desperately trying to heal the "cancerous wound", hMSCs ironically promote cancer progression instead. Yet, currently too little is known about hMSCs to get a clearer picture of what the functions of hMSCs are in cancer progression. Among the many questions that remain are whether hMSCs act primarily on cancer cells as stem cells or as differentiated cells, such as CAFs, and whether, under certain conditions, hMSCs may actually heal "cancerous wounds", which would explain why, in some cases, hMSCs suppress cancer growth. 
